See more : A.P. Møller – Mærsk A/S (DP4B.DE) Income Statement Analysis – Financial Results
Complete financial analysis of China SXT Pharmaceuticals, Inc. (SXTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of China SXT Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Xero Limited (XROLF) Income Statement Analysis – Financial Results
- Poujoulat SA (ALPJT.PA) Income Statement Analysis – Financial Results
- Kyosan Electric Manufacturing Co., Ltd. (6742.T) Income Statement Analysis – Financial Results
- Paramount Global (VIACP) Income Statement Analysis – Financial Results
- Ipca Laboratories Limited (IPCALAB.NS) Income Statement Analysis – Financial Results
China SXT Pharmaceuticals, Inc. (SXTC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sxtchina.com
About China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.93M | 1.97M | 2.60M | 4.78M | 5.16M | 7.01M | 7.02M | 4.88M | 3.72M |
| Cost of Revenue | 1.37M | 1.55M | 1.35M | 1.94M | 2.46M | 2.40M | 3.62M | 2.57M | 2.92M |
| Gross Profit | 553.97K | 426.27K | 1.25M | 2.84M | 2.70M | 4.61M | 3.40M | 2.31M | 793.99K |
| Gross Profit Ratio | 28.73% | 21.62% | 48.10% | 59.43% | 52.37% | 65.77% | 48.46% | 47.36% | 21.35% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.64M | 5.65M | 5.52M | 3.45M | 2.46M | 1.24M | 1.26M | 565.46K | 433.82K |
| Selling & Marketing | 433.57K | 387.45K | 924.54K | 1.59M | 1.58M | 1.61M | 512.48K | 144.36K | 151.03K |
| SG&A | 3.07M | 6.03M | 6.44M | 5.04M | 4.04M | 2.84M | 1.77M | 709.82K | 584.85K |
| Other Expenses | 0.00 | 149.51K | -181.58K | 871.65K | -73.77K | 27.14K | -3.80K | 18.40K | 0.00 |
| Operating Expenses | 3.07M | 6.03M | 6.44M | 5.04M | 4.04M | 2.84M | 1.77M | 709.82K | 584.85K |
| Cost & Expenses | 4.44M | 7.58M | 7.79M | 6.97M | 6.50M | 5.24M | 5.39M | 3.28M | 3.51M |
| Interest Income | 0.00 | 476.78K | 36.70K | 1.11M | 3.35M | 5.17K | 0.00 | 0.00 | 51.06K |
| Interest Expense | 544.28K | 476.78K | 218.28K | 1.62M | 3.35M | 5.17K | 779.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 203.25K | 250.16K | 320.01K | 345.41K | 331.84K | 180.92K | 129.44K | 99.23K | 88.96K |
| EBITDA | -2.35M | -5.21M | -5.05M | -1.85M | -1.01M | 1.95M | 1.76M | 1.70M | 298.11K |
| EBITDA Ratio | -121.91% | -271.71% | -187.13% | -38.76% | 89.43% | 27.82% | 25.04% | 34.85% | 8.02% |
| Operating Income | -2.52M | -5.61M | -5.19M | -2.20M | 4.28M | 1.77M | 1.63M | 1.60M | 209.14K |
| Operating Income Ratio | -130.42% | -284.40% | -199.43% | -45.99% | 83.00% | 25.24% | 23.25% | 32.82% | 5.62% |
| Total Other Income/Expenses | -583.32K | -327.26K | -218.28K | -743.79K | -9.05M | 21.97K | -4.58K | -21.99K | -20.42K |
| Income Before Tax | -3.10M | -5.93M | -5.41M | -2.94M | -10.39M | 1.79M | 1.63M | 1.58M | 188.73K |
| Income Before Tax Ratio | -160.67% | -301.00% | -207.82% | -61.56% | -201.26% | 25.55% | 23.19% | 32.37% | 5.08% |
| Income Tax Expense | 0.00 | 476.78K | 328.15K | -192.68K | -101.72K | 252.23K | 440.10K | 395.05K | 47.18K |
| Net Income | -3.10M | -5.93M | -5.74M | -2.75M | -10.29M | 1.54M | 1.19M | 1.19M | 141.54K |
| Net Income Ratio | -160.67% | -301.00% | -220.43% | -57.52% | -199.29% | 21.95% | 16.92% | 24.28% | 3.81% |
| EPS | -3.57 | -22.23 | -137.92 | -95.48 | -832.08 | 149.67 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -3.57 | -22.23 | -137.92 | -95.48 | -832.08 | 149.67 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 867.42K | 266.97K | 41.59K | 28.78K | 12.36K | 10.28K | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 867.42K | 266.97K | 41.59K | 28.78K | 12.36K | 10.28K | 0.00 | 0.00 | 0.00 |
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split
Why Is China SXT Pharmaceuticals (SXTC) Stock Up 24% Today?
Why Is China SXT Pharmaceuticals (SXTC) Stock Up 110% Today?
China SXT Pharmaceuticals (SXTC) Stock: 1-For-20 Reverse Split Goes Into Effect
Best Penny Stocks, How To Buy & Strategies for Beginners
Why Is China SXT Pharmaceuticals (SXTC) Stock Up Today?
Trading Penny Stocks? Top Stock Market News for March 29th, 2022
Best Penny Stocks To Buy? 5 Explosive Stocks Under $1 To Watch Now
Source: https://incomestatements.info
Category: Stock Reports